nativ
tropism
viru
often
meet
therapeut
need
avoid
toxic
side
effect
natur
tropism
vector
must
often
ablat
diminish
vector
might
also
need
engin
infect
target
cell
infect
natur
target
cell
easili
isol
patient
exampl
blood
bone
marrow
retransf
ex
vivo
gene
transfer
might
ideal
broaden
vector
tropism
might
advantag
altern
local
applic
might
suffici
exampl
local
restrict
tumour
small
organ
eye
depend
possibl
side
effect
gene
transfer
local
nontarget
cell
broaden
narrow
tropism
might
requir
final
system
treatment
might
necessari
exampl
reach
dissemin
metastas
larg
number
somat
cell
correct
genet
defect
situat
tropism
must
narrow
target
cell
discuss
new
approach
aim
improv
viral
vector
target
focus
mainli
system
target
promis
eas
applic
great
therapeut
return
sever
obstacl
need
overcom
order
systemat
appli
vector
reach
target
cell
box
challeng
wide
studi
focu
final
step
infect
target
cell
accomplish
vector
must
display
suitabl
ligand
bind
targetcel
receptor
natur
tropism
virus
match
vector
util
case
herp
viru
use
neuron
gene
deliveri
protein
part
viru
vector
bind
cellular
receptor
attent
research
mainli
owe
fact
studi
easier
availabl
vitro
model
box
unlik
obstacl
discuss
box
progress
vector
develop
achiev
use
adenoviru
ad
adenoassoci
viru
aav
vector
deriv
retrovirus
particularli
lentivirus
tabl
technic
hurdl
must
overcom
develop
effect
therapeut
system
similar
viral
vector
system
method
enhanc
one
vector
system
often
gener
relev
discuss
main
approach
appli
vector
target
outlin
import
challeng
need
address
order
gene
therapi
use
viral
vector
reach
widespread
clinic
applic
vector
target
pseudotyp
pseudotyp
first
method
use
alter
viral
vector
tropism
involv
transfer
viral
attach
protein
either
strain
within
famili
virus
viru
famili
fig
tabl
pseudotyp
achiev
cotransfect
plasmid
one
encod
attach
protein
pseudotyp
separ
plasmid
encod
vector
compon
approach
use
routin
pseudotyp
aav
retrovir
lentivir
vector
altern
viral
attach
protein
express
tran
product
cell
line
genet
incorpor
viral
genom
approach
particularli
well
suit
gener
adenoviru
pseudotyp
pseudotyp
envelop
vector
pseudotyp
use
extens
modul
hostcel
tropism
retrovir
includ
lentivir
vector
highli
permiss
incorpor
heterolog
attach
glycoprotein
wide
use
retrovir
vector
pseudotyp
incorpor
attach
glycoprotein
vesicular
stomat
viru
vsvg
allow
product
hightitr
vector
stock
confer
broad
host
rang
list
foreign
envelop
glycoprotein
incorpor
lentivir
vector
long
includ
repres
sever
viru
famili
pseudotyp
show
larg
differ
rel
transduct
effici
differ
tissu
notabl
vivo
find
includ
high
effici
neural
tissu
transduct
lyssaviru
pseudotyp
rabi
mokola
virus
effici
transduct
airway
epithelium
filoviru
ebola
zair
paramyxoviru
sendai
pseudotyp
lentivir
gene
transfer
gain
broader
accept
clinic
viabl
vector
system
vector
could
use
explor
gene
therapi
parkinson
diseas
cystic
fibrosi
respect
ad
serotyp
bind
receptor
car
coxsacki
adenoviru
receptor
fibr
knob
subsequ
integrin
interact
rgd
peptid
motif
penton
base
capsid
protein
base
fibr
facilit
cell
entri
endocytosi
b
adenoassoci
viru
aav
sever
basic
residu
adenoassoci
viru
serotyp
capsid
protein
especi
posit
involv
heparin
bind
first
bind
heparansulph
proteoglycan
hspg
coreceptor
either
integrin
shown
human
fibroblast
growth
factor
receptor
hepatocyt
growth
factor
receptor
viru
intern
endocytosi
aav
serotyp
either
resembl
heparin
bind
use
differ
primari
receptor
exampl
sialic
acid
c
retroviru
lentiviru
membran
fusion
main
mechan
wherebi
envelop
virus
deliv
genom
target
cell
initi
nonspecif
adhes
viru
cell
surfac
viral
attach
glycoprotein
bind
specif
cognat
receptor
whereupon
bind
becom
irrevers
host
rang
retrovir
vector
determin
interact
viral
envelop
protein
env
cellular
receptor
subsequ
step
viral
entri
process
vari
differ
virus
alway
result
fusion
lipid
membran
viru
host
cell
follow
viral
nucleocapsid
releas
cytoplasm
case
receptor
bind
trigger
conform
chang
viral
protein
mediat
membran
fusion
other
cellbound
viru
transport
receptor
endosom
compart
reduct
ph
trigger
conform
rearrang
viral
fusion
machineri
su
surfac
subunit
tm
transmembran
subunit
intric
network
minut
blood
vessel
extend
tissu
bodi
one
part
simpl
virus
character
ctype
morpholog
genu
member
retrovirus
famili
includ
murin
leukaemia
virus
felin
leukaemia
virus
gibbon
ape
leukaemia
viru
unfortun
specif
natur
occur
viral
attach
protein
frequent
coincid
requir
target
gene
deliveri
respons
sever
encourag
studi
demonstr
feasibl
pseudotyp
retrovir
vector
chimer
envelop
glycoprotein
sindbi
virus
gammaretrovirus
genet
engin
incorpor
polypeptid
ligand
direct
target
specif
cell
type
see
later
detail
discuss
genet
incorpor
target
ligand
virus
mani
retrovir
target
approach
howev
accuraci
often
come
price
low
genetransf
effici
via
target
receptor
optim
effici
target
gene
transfer
need
justifi
clinic
test
concept
pseudotyp
recent
extend
incorpor
hostcel
viral
receptor
viral
envelop
target
entri
hivinfect
cell
feasibl
demonstr
use
replicationcompet
rhabdoviru
vsv
nonrepl
lentivir
murin
leukaemia
viru
mlv
vector
mediat
target
destruct
hivinfect
cell
redirect
use
hivderiv
glycoprotein
receptor
howev
effici
target
entri
hivinfect
cell
low
reason
understood
pseudotyp
also
use
nonenvelop
vector
includ
aav
adenoviru
import
challeng
viral
attach
protein
must
incorpor
protein
capsid
instead
lipid
bilay
mainli
achiev
substitut
coat
protein
homolog
protein
relat
serotyp
give
rise
new
tropism
without
chang
rest
genom
thu
enabl
use
establish
clone
system
develop
previou
serotyp
also
possibl
incorpor
coat
protein
unrel
virus
although
structur
incompat
preclud
exampl
basi
structur
similar
trimer
ad
fibr
trimer
reoviru
attach
protein
chimer
protein
introduc
ad
capsid
modifi
ad
genom
enabl
effici
infect
primari
dendrit
cell
intestin
epitheli
cell
case
structur
incompat
hinder
incorpor
desir
part
foreign
viral
attach
protein
artifici
fibr
molecul
use
exampl
exploit
fuse
singlechain
variabl
fragment
scfv
antibodi
ad
vector
current
eukaryot
viral
vector
infect
cell
high
effici
disadvantag
nativ
tropism
must
ablat
achiev
liganddirect
target
upon
system
administr
prokaryot
virus
infect
mammalian
cell
low
effici
best
adapt
bind
mammalian
receptor
genet
engin
eukaryot
ligand
capsid
exampl
one
studi
report
construct
hybrid
vector
compris
aav
cassett
insert
phage
genom
target
v
integrin
argglyasp
peptid
motif
display
phage
capsid
follow
system
applic
nude
mice
vector
show
specif
target
tumour
deriv
inject
human
prostat
cancer
cell
tumour
shrinkag
achiev
therapeut
transgen
introduc
vector
monitor
biodistribut
vector
studi
facilit
use
vivo
vector
imag
remark
chimer
vector
also
highli
effect
antitumour
therapi
context
immunocompet
mice
even
follow
prior
phage
vaccin
high
antiphag
antibodi
titr
similar
strategi
could
use
vector
doublestrand
genom
adenovirus
mani
obstacl
system
deliveri
studi
thoroughli
adenoviru
ad
still
need
address
system
term
impact
might
overcom
howev
area
discuss
like
relev
vector
first
potenti
hurdl
vector
found
form
immun
system
factor
blood
circulatori
system
reaction
complement
system
preexist
antibodi
either
natur
occur
previou
vector
applic
imped
vector
reach
target
coat
ad
vector
polyethylen
glycol
peg
help
escap
antibodymedi
innat
immun
respons
combin
target
modif
otherwis
reduc
effici
gene
transfer
blood
factor
exampl
coagul
factor
ix
complement
protein
bind
adenovir
fibr
redirect
viru
bloodstream
liver
via
uptak
heparansulph
proteoglycan
ldlreceptorrel
protein
furthermor
ad
interact
human
blood
cell
erythrocyt
neutrophil
monocyt
prevent
vector
reach
target
serotyp
switch
modif
capsid
protein
may
circumv
interact
next
hurdl
endotheli
cell
layer
vector
must
exit
bloodstream
right
tissu
move
beyond
endotheli
cell
line
transduc
target
cell
vascular
bed
access
vector
exit
exampl
ad
exit
liver
vector
natur
possess
mechan
allow
transcytosi
beyond
endothelium
exampl
aav
subtyp
hiv
cross
certain
monolay
howev
case
vascular
bed
present
barrier
vector
unabl
cross
endothelium
necessit
vector
modif
engin
abil
undergo
transcytosi
one
potenti
mechan
achiev
transit
anoth
method
involv
use
cellular
vehicl
stem
cell
carri
vector
home
target
tissu
cellular
vehicl
might
especi
help
one
need
overcom
extracellular
matrix
separ
target
cell
exampl
tumour
cell
endothelium
enter
correct
target
tissu
final
step
vector
infect
target
cell
fig
discuss
detail
main
text
addit
obstacl
exist
tumour
target
despit
fact
lesion
access
system
treatment
experiment
model
model
fulli
recapitul
clinic
scenario
frequent
tumourcel
islet
surround
basalmembranelik
structur
within
stromal
cell
one
anim
model
blood
vessel
observ
direct
contact
stromal
cell
vector
would
need
cross
stroma
basalmembranelik
structur
reach
tumour
might
possibl
overcom
obstacl
use
stem
cell
carri
vector
first
target
surround
area
tumour
weaken
stromaand
basalmembranelik
structur
exampl
matrix
metalloproteinas
target
tumour
howev
target
tumour
environ
might
suffici
therapeut
effect
least
case
antigen
distinct
form
microorgan
includ
virus
elicit
differ
antibodi
respons
immun
system
attach
protein
adenovir
vector
threedimension
aggreg
purifi
unpassag
cancer
cell
agent
induc
lysi
tumour
cell
vector
target
use
adaptor
pseudotyp
limit
number
viral
attach
protein
receptor
express
exclus
abundantli
target
cell
interest
genet
modif
overcom
limit
requir
structur
knowledg
guid
modif
viral
attach
protein
knowledg
becom
avail
use
adaptor
protein
appli
even
limit
knowledg
viral
structur
explor
altern
adaptor
molecul
dual
specif
one
end
bind
viral
attach
protein
bind
receptor
target
cell
advantag
approach
great
flexibl
differ
adaptor
readili
coupl
vector
fact
requir
chang
vector
structur
could
detriment
vector
product
gene
transfer
adaptor
achiev
two
main
goal
target
deliveri
ablat
nativ
tropism
confer
novel
tropism
toward
desir
target
adaptor
system
prove
particularli
use
proofofprincipl
preclin
studi
allow
easi
test
sever
target
receptor
receptorligand
complex
import
class
adaptor
exploit
nativ
viral
tropism
wide
use
retarget
vector
viral
receptor
genet
fuse
ligand
receptor
express
target
cell
exampl
fuse
ectodomain
adenoviru
receptor
coxsacki
adenoviru
receptor
car
ligand
receptor
dendrit
cell
trimer
motif
success
target
ad
vector
dendrit
cell
four
order
magnitud
higher
effici
untarget
ad
vector
fig
fuse
ectodomain
car
singlechain
antibodi
human
carcinoembryon
antigen
cea
allow
vector
target
subcutan
tumour
well
hepat
metastas
colon
cancer
nude
mice
simultan
ablat
liver
tropism
principl
appli
retrovir
vector
fusion
extracellular
domain
avian
sarcoma
leukaemia
viru
aslv
retrovir
receptor
tumour
viru
subgroup
receptor
tva
success
target
vector
cell
express
heregulin
receptor
provid
potenti
therapeut
strategi
treatment
variou
malign
adaptor
incorpor
aslv
receptor
virusbind
moieti
explor
particular
trigger
conform
chang
aslv
envelop
glycoprotein
requir
membran
fusion
viru
entri
anoth
import
exampl
type
target
achiev
one
coronavirus
class
envelop
rna
virus
potenti
oncolyt
agent
tropism
replicationcompet
coronaviru
mous
hepat
viru
mhv
recent
retarget
engin
viral
genom
express
adaptor
protein
consist
part
natur
cellular
receptor
mhv
target
peptid
allow
multiround
infect
kill
target
cell
altogeth
receptorligand
approach
show
promis
use
rang
preclin
studi
howev
clinic
applic
target
method
genet
target
discuss
might
prefer
potenti
risk
adaptor
could
dissoci
vector
chemic
conjug
method
coupl
adaptor
vector
target
ligand
coval
link
vector
polyethylen
glycol
peg
pegderiv
polym
use
coupl
ad
vector
ligand
fibroblast
growth
factor
use
target
ovarian
cancer
cell
endotheli
cell
also
target
use
approach
coupl
ad
vector
peg
cellcultur
system
first
step
evalu
target
capabl
vector
usual
test
cell
line
howev
limit
predict
valu
vivo
scenario
exampl
cell
line
overexpress
viral
receptor
rel
clinic
relev
primari
cell
twodimension
cellcultur
system
also
limit
predict
valu
usual
repres
one
two
cell
type
grown
artifici
surfac
artifici
twodimension
context
first
step
toward
threedimension
cultur
primarytumour
spheroid
use
evalu
target
ad
vector
vector
test
replic
compet
tumour
cell
show
gradual
penetr
spheroid
howev
spheroid
almost
exclus
compos
tumour
cell
wherea
within
natur
occur
tumour
therapeut
effect
modifi
presenc
stromal
cell
extracellular
matrix
anoth
drawback
twodimension
cultur
system
assess
anticanc
gene
therapi
mediat
viral
vector
possibl
toxic
effect
stromal
cell
evalu
threedimension
cellcultur
model
includ
endotheli
cell
fibroblast
immunocompet
cell
extracellular
matrix
although
current
expens
threedimension
scaffold
provid
promis
system
emul
nativ
structur
live
tissu
could
becom
valuabl
tool
vector
test
tissu
explant
next
step
sophist
model
system
use
tissu
explant
exampl
tissueslic
system
use
evalu
target
tissu
although
system
directli
resembl
system
administr
valuabl
data
concern
transduct
target
nontarget
tissu
easili
obtain
system
avail
differ
applic
time
implement
target
studi
recent
one
exampl
approach
use
analys
target
ad
vector
transduct
breast
tumour
liver
cell
anoth
tissu
explant
model
repres
human
skin
substrat
system
plastic
surgeri
frequent
yield
skin
use
ex
vivo
evalu
vector
target
model
recent
prove
potenti
use
gene
therapi
assess
context
ad
vector
target
dendrit
cell
anim
model
although
circulatori
system
compar
human
anim
model
limit
respect
evalu
transduct
target
exampl
express
human
receptor
case
xenotransplant
model
cancer
research
lack
complet
immun
system
new
immunocompet
transgen
mous
model
express
human
receptor
develop
evalu
vector
target
exampl
transgen
mice
gener
express
human
express
pattern
similar
human
receptor
sever
virus
mous
model
use
evalu
pseudotyp
vector
case
ectop
transgen
express
human
receptor
mous
model
suffic
relev
mous
model
promis
reduc
effort
cost
compar
need
gener
transgen
model
target
system
recent
develop
use
evalu
target
adenovir
vector
coupl
adpeg
complex
rgd
peptid
eselectinantibodi
importantli
pegyl
potenti
shield
vector
innat
immun
system
vivo
allow
infect
presenc
ad
antibodi
might
enabl
repeat
vector
applic
wherea
pegyl
imped
cell
transduct
vitro
effect
seem
occur
vivo
possibl
owe
differ
hydrodynam
condit
far
target
pegyl
use
aav
ad
vector
could
potenti
extend
envelop
vector
pegyl
strategi
recent
develop
promis
extens
chemic
conjug
approach
recent
introduc
studi
combin
flexibl
adaptor
system
advantag
stabl
coval
bond
provid
genet
target
see
highli
reactiv
thiol
group
introduc
ad
capsid
genet
insert
cystein
solventexpos
posit
thiol
group
coupl
transferrin
mediat
success
target
vector
cell
express
receptor
protein
thiol
group
tip
fibr
thu
distant
surfac
amino
group
use
pegyl
system
use
simultan
novel
thiolgroup
coupl
system
allow
conveni
introduct
fulllength
protein
transferrin
also
receptor
ligand
introduc
genet
method
sugar
fatti
acid
small
molecul
approach
potenti
extend
vector
system
possibl
except
envelop
vector
vector
lack
necessari
capsid
site
modif
addit
coupl
env
protein
retrovir
lentivir
viral
envelop
protein
might
deleteri
function
chemic
step
involv
might
disrupt
viral
envelop
adaptor
system
use
avidin
biotin
highaffin
bind
avidin
biotin
use
mani
biotechnolog
applic
gene
therapist
taken
advantag
provid
adaptor
strategi
exploit
sever
viral
vector
form
valuabl
basi
target
studi
one
first
studi
demonstr
feasibl
approach
envelop
viru
report
long
ago
ref
ecotrop
retroviru
crosslink
human
major
histocompat
complex
class
mhci
adaptor
strategi
viru
coat
biotinyl
antienvelop
antibodi
streptavidin
final
biotinyl
antimhc
antibodi
redirect
attach
although
entri
via
class
mhc
convincingli
demonstr
vitro
effici
approach
low
reason
fulli
determin
emerg
replicationcompet
vector
vivo
possibl
major
concern
neglig
low
risk
possibl
major
concern
risk
concern
risk
concern
infect
quiescent
cell
biotinyl
strategi
also
develop
ad
vector
biotinacceptor
peptid
bap
clone
fibr
capsid
protein
produc
adbap
fusion
bap
biotinyl
vector
product
mammalian
cell
therefor
coupl
biotinyl
target
ligand
via
tetramer
avidin
fig
compar
coat
vector
biotinyl
antibodi
strategi
make
use
robust
coval
attach
biotin
vector
approach
use
screen
potenti
target
ligand
purifi
adenovir
vector
evalu
ad
capsid
protein
target
term
potenti
clinic
applic
avidinbiotin
system
use
target
ad
vector
dendrit
cell
vitro
use
monoclon
antibodi
highaffin
bind
peptid
ligand
target
cell
receptor
highaffin
bind
avidin
biotin
qualifi
system
vivo
applic
includ
therapeut
one
possibl
toxic
high
level
avidin
complex
biotin
circul
could
concern
howev
consid
risk
low
vectorbound
avidin
expect
introduc
patient
retrovir
lentivir
vector
pseudotyp
envelop
protein
env
differ
viru
b
adaptor
part
ba
adenovir
vector
coupl
receptorligand
fusion
exampl
ectodomain
adenovir
receptor
fuse
ligand
express
target
cell
type
exampl
ligand
receptor
dendrit
cell
part
bb
biotinacceptor
peptid
integr
fibr
knob
biotinyl
coupl
avidincontain
ligand
part
bc
antibodybind
domain
genet
incorpor
adenoassoci
viru
aav
capsid
coupl
monoclon
antibodi
vector
part
bd
bispecif
antibodi
attach
aav
capsid
c
genet
incorpor
target
ligand
part
ca
singlechain
antibodi
singlechain
variabl
fragment
scfv
human
carcinoembryon
antigen
cea
matrix
metalloproteas
mmp
cleavag
site
coupl
viral
envelop
protein
env
allow
bind
tumour
cell
express
cea
follow
cleavag
mmp
cleavag
site
tumoursecret
mmp
vector
also
target
tumour
cell
incorpor
tumourspecif
scfv
directli
env
howev
insert
perturb
infect
target
receptor
support
requir
postbind
step
toward
viral
entri
mmp
cleavag
site
allow
releas
scfv
fusion
target
cell
part
cb
incorpor
small
target
ligand
exampl
rgd
peptid
use
target
vector
integrin
receptor
part
cc
serotyp
chang
achiev
desir
target
part
cd
use
differ
fibr
vector
allow
multifunction
mosaic
fibr
viru
car
coxsacki
adenoviru
receptor
aav
vector
biotinyl
similar
way
ad
vector
system
use
platform
purif
target
vector
type
differ
biotinyl
approach
recent
taken
vaccinia
viral
vector
prove
success
vitro
target
viru
chemic
biotinyl
follow
addit
avidin
subsequ
incub
biotinyl
antibodi
allow
target
mhciand
tumour
cell
avidinbiotin
system
seem
suitabl
recent
test
biodistribut
target
vector
requir
sacrif
anim
evalu
transgen
express
viral
particl
concentr
variou
organ
sever
clinic
trial
shown
lack
use
end
point
would
allow
evalu
vector
target
approach
allow
imag
viral
vector
distribut
vivo
advantag
anim
need
sacrif
analysi
enabl
multipl
realtim
measur
vector
distribut
vector
novel
modal
allow
vivo
imag
develop
imag
moieti
gener
either
express
form
report
transgen
viral
genom
attach
vector
genet
fusion
capsid
protein
genebas
imag
make
use
radioact
system
vectormedi
gene
transfer
herp
simplex
thymidin
kinas
phosphoryl
radiolabel
nucleosid
analogu
quantif
carri
use
positron
emiss
tomographi
pet
imag
applic
clinic
set
altern
lightemit
system
use
includ
use
luciferas
green
red
fluoresc
protein
recent
exampl
illustr
imag
greatli
facilit
evalu
target
approach
lentivir
vector
pseudotyp
envelop
protein
env
sindbi
viru
success
retarget
metastat
melanoma
vivo
achiev
sindbi
env
mutat
ablat
liver
spleen
tropism
zz
domain
igbind
domain
protein
genet
fuse
protein
allow
coupl
monoclon
antibodi
target
pglycoproteinexpress
melanoma
cell
see
part
figur
biodistribut
monitor
imag
facilit
vectormedi
luciferas
express
part
b
figur
show
ablat
nativ
tropism
vector
scid
sever
combin
immunodefici
mice
inject
system
lentiviru
pseudotyp
sindbi
env
protein
contain
antibodybind
domain
upper
panel
show
strong
liver
spleen
tropism
owe
domain
within
sindbi
env
protein
target
vector
tissu
mutat
domain
larg
ablat
natur
tropism
shown
lower
panel
light
emiss
measur
photon
p
cm
steridian
sr
part
c
mice
inject
first
tumour
cell
form
lung
metastas
day
later
vector
use
nonspecif
control
antibodi
lead
tumourcel
transduct
shown
upper
panel
wherea
use
tumourcellspecif
antibodi
lead
transduct
tumour
cell
lung
lower
panel
studi
show
combin
sever
target
techniqu
pseudotyp
ablat
nativ
tropism
adaptor
coupl
lead
truli
target
gene
transfer
system
applic
imag
essenti
analysi
ad
vector
recent
becom
possibl
incorpor
imag
ligand
capsid
green
red
fluoresc
protein
herp
simplex
viru
thymidin
kinas
hsvtk
hsvtkluciferas
fusion
protein
fuse
capsid
protein
pix
allow
multimod
imag
case
imag
ligand
retain
activ
local
imag
signal
capsid
label
seem
especi
promis
context
track
intracellular
fate
vector
would
possibl
otherwis
observ
spread
target
oncolyt
vector
anoth
approach
exploit
magnet
reson
imag
mri
use
gene
therapi
context
recent
becam
applic
direct
vector
imag
et
al
use
mribas
imag
avidinco
baculoviru
conjug
biotinyl
superparamagnet
iron
oxid
particl
techniqu
easili
applic
capsidco
virus
spatial
resolut
mri
millimetr
typic
medic
mri
micrometr
typic
research
mri
rang
much
greater
imag
method
gener
resolut
sever
millimetr
allow
assign
vector
locat
individu
cell
howev
mri
consider
less
sensit
radioact
lightbas
imag
system
vector
type
allow
incorpor
bap
chemic
biotinyl
techniqu
univers
applic
expect
util
mani
applic
futur
mani
research
work
way
capit
divers
wide
avail
reagent
vector
genet
modifi
allow
coupl
monoclon
antibodi
exampl
region
bacteri
immunoglobulin
ig
bind
protein
usual
zdomain
staphylococcu
protein
insert
viral
attach
protein
variou
vector
system
way
unmodifi
antibodi
work
like
adaptor
bridg
igbind
domain
incorpor
vector
target
receptor
antibodi
specif
fig
approach
success
use
vitro
scid
sever
combin
immunodefici
mice
howev
signific
limit
approach
polyclon
ig
bloodstream
might
compet
displac
monoclon
antibodi
viral
display
igbind
protein
reach
target
site
approach
yet
advanc
clinic
test
might
better
suit
ex
vivo
gene
therapi
applic
requir
transduct
specif
target
cell
mix
cell
popul
exampl
stem
cell
bone
marrow
adaptor
system
describ
disadvantag
detract
potenti
use
gene
therapi
one
disadvantag
relat
potenti
suboptim
stabil
vectoradaptor
complex
especi
vivo
might
result
unforeseen
interact
factor
perturb
noncoval
bind
system
reli
either
bap
strong
bind
target
complex
chemic
conjug
least
like
affect
addit
difficulti
aris
term
scale
adaptor
protein
product
coupl
effici
might
vari
differ
batch
final
regulatori
agenc
favour
singlecompon
system
consid
adaptor
viru
separ
drug
one
perceiv
problem
crosslink
might
elut
surfac
viru
vivo
adaptor
approach
also
consid
cumbersom
clinic
applic
none
adaptor
approach
test
extens
vivo
limit
understand
potenti
util
system
base
bap
great
flexibl
expect
wide
appli
includ
potenti
patient
system
like
greatest
potenti
preclin
proofofprincipl
studi
avoid
potenti
complex
adaptor
system
research
investig
method
genet
incorpor
target
ligand
viral
vector
genet
fusion
ligand
capsid
envelop
protein
yield
singl
virion
molecul
recogn
target
cell
despit
technic
challeng
use
adaptor
singlecompon
system
provid
homogen
retarget
vector
particl
unlik
adaptorbas
approach
well
overcom
regulatori
issu
twocompon
system
approach
facilit
hightitr
product
elimin
need
creat
separ
adaptor
molecul
system
involv
polypeptid
ligand
sever
promis
singlecompon
system
involv
genet
incorpor
polypeptid
ligand
viral
surfac
protein
give
vector
new
highli
specif
tropism
cell
express
target
antigen
approach
pioneer
display
singlechain
antibodi
surfac
envelop
viru
case
antihapten
antibodi
genet
fuse
near
nterminu
mlv
surfac
su
compon
envelop
glycoprotein
retrovir
vector
incorpor
chimer
protein
shown
bind
hapten
via
display
antibodi
singlechain
antibodi
approach
appli
sever
vector
aav
adenoviru
retroviru
fig
measl
viru
herp
simplex
viru
underlin
versatil
approach
mani
complex
polypeptid
ligand
includ
growth
factor
cytokin
sinc
display
variou
gammaretrovir
envelop
glycoprotein
either
ntermin
fusion
insert
prolinerich
hing
region
substitut
ntermin
protein
domain
similar
engin
attempt
envelop
virus
ligand
fuse
proxim
ntermini
herpesviru
protein
gc
gd
influenza
haemagglutinin
vsvg
protein
ligand
insert
within
ntermin
receptorbind
domain
attach
protein
sindbi
viru
despit
great
potenti
approach
term
specif
one
limit
appli
gener
introduct
larg
protein
deleteri
structur
viral
protein
insert
imped
correct
fold
incorpor
polypeptid
incorpor
singlechain
antibodi
fusion
ad
vector
initi
imped
differ
biosynthet
pathway
use
produc
scfv
synthes
rough
endoplasm
reticulum
er
facilit
format
disulphid
bridg
ad
capsid
protein
synthes
cytosol
interf
format
bridg
addit
incorpor
larg
protein
ad
fibr
imped
proper
fold
trimer
fibr
henc
viral
rescu
use
cytosol
stabil
scfv
intrabodi
gener
artifici
fibr
allow
genet
coupl
fibr
scfv
ad
system
artifici
fibr
ad
advantag
ablat
nativ
tropism
ad
one
challeng
use
system
relat
identifi
scfv
fold
correctli
cytosol
requir
expertis
scfv
technolog
complex
fibr
amphotrop
describ
pathogen
viru
bacteria
wide
host
rang
infect
one
speci
cellcultur
line
modif
contrast
glycoprotein
envelop
vector
rout
er
support
fold
posttransl
modif
complex
protein
fuse
envelop
thu
polypeptid
ligand
multipl
disulphid
bond
stringent
glycosyl
requir
oligomer
structur
readili
display
envelop
virus
nonenvelop
virus
target
viru
attach
necessarili
lead
target
entri
case
retrovir
envelop
glycoprotein
display
target
ligand
usual
imped
infect
normal
function
viral
attach
protein
alter
lead
direct
viru
nonfunct
entri
pathway
steric
block
natur
receptor
interact
prevent
conform
chang
requir
effect
fusion
trigger
problem
led
concept
invers
target
wherebi
viral
envelop
glycoprotein
modifi
select
destroy
infect
cell
express
target
receptor
thu
amphotrop
retrovir
vector
display
epiderm
growth
factor
egf
stemcel
factor
scf
insulinlik
growth
factor
select
noninfecti
cell
express
cognat
receptor
egfr
kit
igfr
remain
fulli
infecti
receptorneg
human
cell
invers
target
provid
use
way
detarget
liver
egfr
posit
marrow
stem
cell
kit
posit
use
amelior
specif
vector
toxic
target
although
number
potenti
applic
limit
proteas
target
anoth
concept
emerg
earli
unsuccess
effort
reprogramm
retroviru
entri
viru
infect
engin
depend
proteolyt
matur
viral
surfac
protein
achiev
cleavag
proteasesuscept
linker
tether
infectivityblock
polypeptid
viral
surfac
anoth
approach
cleavag
engin
junction
sequenc
su
transmembran
tm
compon
retrovir
envelop
glycoprotein
compon
measl
attach
glycoprotein
way
vector
target
cell
bath
appropri
proteas
exampl
includ
target
proteaserich
tumour
vector
infect
select
activ
matrix
metalloproteinas
mmp
fig
plasmin
potenti
proteaserich
target
includ
site
new
blood
vessel
format
diabet
retinopathi
pannu
tissu
joint
affect
rheumatoid
arthriti
well
site
acut
chronic
inflamm
sever
anim
studi
demonstr
feasibl
vivo
transduct
target
use
retrovir
lentivir
vector
genet
incorpor
polypeptid
ligand
one
studi
retrovir
vector
activ
mmp
display
melanomatarget
singlechain
antibodi
shown
target
gene
deliveri
mmprich
melanoma
xenograft
anoth
studi
liver
success
detarget
pseudotyp
lentivir
vector
amphotrop
mlv
envelop
glycoprotein
display
egf
ntermin
fusion
reduc
hepat
transduct
case
result
invers
target
possibl
egf
receptor
express
abundantli
hepatocyt
third
exampl
repres
first
far
target
vector
test
clinic
retrovir
vector
rex
express
cytocid
dominantneg
form
cyclin
vector
display
collagenbind
portion
von
willebrand
factor
vwf
requir
adhes
platelet
site
injur
endothelium
incorpor
env
protein
exploit
target
mechan
allow
preferenti
vector
deliveri
tumour
site
angiogenesi
collagen
matrix
exposur
occur
tumour
neovessel
rex
target
extracellular
matrix
tumour
tissu
test
antitumour
activ
three
clinic
studi
sever
case
partial
respons
stabl
diseas
demonstr
effect
vector
limit
encount
retrovir
lentivir
vector
target
use
engin
polypeptid
ligand
necessarili
appli
envelop
virus
contrast
retrovirus
attach
fusion
function
measl
viru
encod
separ
protein
make
easier
manipul
bind
specif
without
neg
impact
effici
fusion
trigger
see
howev
measl
still
viru
effici
retarget
wide
rang
cellular
receptor
use
varieti
celltarget
polypeptid
without
signific
reduct
entri
effici
smallpeptid
motif
smallpeptid
motif
less
like
perturb
structur
viral
attach
protein
permit
insert
variou
region
protein
despit
small
size
gener
amino
acid
chang
target
characterist
vector
dramat
small
peptid
contain
rgd
motif
target
vector
integrin
often
use
purpos
facilit
divers
applic
includ
target
vasculatur
tumour
cell
target
achiev
aav
vitro
adenoviru
ex
vivo
tissueslic
assay
vivo
retrovir
vector
vitro
fig
phageaav
hybrid
vector
vivo
anoth
use
smallpeptid
target
moieti
polylysin
peptid
target
vector
heparan
sulphat
overexpress
number
malign
patholog
adenovir
vector
carri
fibr
knob
show
increas
transduct
variou
cardefici
target
skelet
muscl
vivo
addit
rgd
recent
use
togeth
ad
capsid
improv
effici
vector
deliveri
henc
surviv
murin
model
cancer
gener
modif
broaden
vector
tropism
make
especi
use
local
administr
rgdmodifi
condit
replic
ad
soon
use
clinic
local
applic
ovarian
carcinoma
univers
alabama
birmingham
usa
follow
recent
complet
anim
safeti
test
although
smallpeptid
motif
versatil
use
target
viral
vector
sever
cell
type
cell
type
target
way
requir
differ
target
approach
libraryselect
approach
describ
genet
target
approach
limit
size
sometim
structur
ligand
incorpor
without
compromis
assembl
stabil
infect
vector
also
crucial
display
ligand
maintain
bridg
abil
toward
target
fusion
viral
attach
protein
consider
driven
libraryselect
approach
display
ligand
context
viral
attach
protein
select
desir
increas
infect
bind
column
display
target
receptor
repeat
cycl
bind
target
cell
serial
passag
target
cell
one
exampl
h
sheet
ad
fibr
knob
insert
piii
protein
bacteriophag
random
peptid
librari
introduc
ad
knob
sheet
select
target
cell
result
identif
peptid
improv
ad
transduct
mous
muscl
cell
compar
unmodifi
ad
differ
approach
use
librari
screen
aav
first
aav
capsid
protein
cap
subject
pcrbase
mutagenesi
recombin
follow
insert
aav
packag
plasmid
creation
aav
librari
librari
screen
desir
properti
exampl
use
heparin
affin
chromatographi
select
low
high
heparin
affin
incub
neutral
serum
select
mutant
evad
antibodi
respons
librari
select
chang
retrovir
vector
tropism
also
carri
exampl
one
studi
felin
leukemia
viru
felv
envelop
glycoprotein
random
celltarget
region
oligonucleotid
insert
subject
transductionbas
select
strategi
cancer
cell
result
felv
vector
abl
transduc
prostat
cancer
cell
line
requir
presenc
murin
retroviru
helper
envelop
glycoprotein
facilit
viru
entri
although
exampl
demonstr
feasibl
select
vector
new
tropism
retrovir
librari
select
strategi
focus
specif
known
receptor
focus
particular
cell
type
howev
case
target
ligand
known
libraryselect
approach
provid
one
way
forward
proof
principl
approach
establish
target
major
vector
class
system
applic
nativ
vector
tropism
gene
therapi
vector
might
need
ablat
avoid
transduct
nontarget
tissu
instanc
addit
target
ligand
reduc
nativ
tropism
suffici
exampl
incorpor
peptid
target
human
venou
endotheli
cell
aav
capsid
result
significantli
lower
hepatocyt
transduct
greatli
increas
venouscel
transduct
howev
case
addit
step
must
taken
ablat
nativ
tropism
vector
exampl
ad
serotyp
vector
commonli
use
ad
vector
detarget
central
import
enabl
success
system
treatment
avoid
effect
liver
addit
target
moieti
alon
frequent
insuffici
mani
fibr
mutant
gener
attempt
achiev
liver
detarget
dramat
effect
seen
ad
fibr
delet
put
heparansulph
proteoglycanbind
motif
result
decreas
liver
transduct
decreas
combin
carabl
mutat
howev
effect
detarget
mutat
seem
highli
depend
strain
speci
rodent
highlight
import
use
multipl
complementari
preclin
model
system
exampl
tropism
ablat
regard
retrovir
vector
discuss
context
invers
target
exampl
lentivir
vector
discuss
box
gener
vector
requir
specif
chang
viral
attach
protein
ablat
nativ
tropism
modif
use
wide
rang
applic
except
revers
target
use
envelop
vector
specif
particular
cell
type
altern
approach
use
vector
tropism
target
organ
use
prokaryot
vector
normal
infect
eukaryot
cell
modifi
rgd
motif
system
applic
becom
feasibl
lead
tumourspecif
transduct
shown
aavphag
hybrid
outlook
futur
direct
celltypespecif
target
vivo
gene
therapi
vector
mileston
recent
realiz
applic
direct
translat
achiev
clinic
might
possibl
exampl
local
applic
genet
modifi
vector
broaden
tropism
system
administr
vector
specif
target
ablat
nativ
tropism
could
see
applic
year
therapeut
intervent
requir
research
achiev
desir
target
specif
facilit
sever
recent
develop
exampl
singlecompon
system
ad
artifici
fibr
genet
fuse
scfv
easi
prepar
high
titr
expect
face
problem
clinic
approv
contrast
lentivir
vector
coupl
adaptor
might
face
problem
largescal
prepar
regard
gener
safeti
issu
lentivir
vector
seen
mani
case
challeng
develop
success
target
vector
relat
biolog
individu
vector
type
despit
vast
rang
experiment
studi
carri
target
vector
transit
clinic
set
slow
delay
relat
gener
problem
field
gene
therapi
complement
system
protein
system
blood
form
defens
pathogen
transport
macromolecul
includ
pathogen
across
cell
consist
endocytosi
macromolecul
one
side
monolay
exocytosi
side
concern
high
cost
vector
product
clinic
use
acquisit
financi
support
product
sever
round
clinic
trial
need
optim
particular
gene
therapi
approach
case
therapi
exampl
monoclon
antibodi
need
sever
trial
find
way
clinic
practic
import
aspect
clinic
studi
begun
begin
target
vector
gain
regulatori
food
drug
administr
fda
approv
usa
western
nation
gear
fda
procedur
approv
repres
encourag
sign
target
gene
therapi
protocol
worldwid
although
review
focus
larg
final
step
target
transduct
target
cell
aspect
equal
import
especi
system
vector
administr
briefli
discuss
potenti
obstacl
immun
system
antibodi
complement
system
blood
factor
impact
vector
blood
stream
way
escap
problem
current
investig
exit
vector
blood
stream
target
tissu
also
import
step
address
ensur
vector
move
beyond
vascular
endotheli
layer
system
applic
exampl
transcytosi
crucial
import
achiev
clinic
success
mani
instanc
dissemin
metastas
strategi
enabl
transcytosi
recent
move
forefront
vector
target
research
wherea
transcytosi
lentiviru
hiv
describ
area
begin
explor
virus
form
basi
type
gene
therapi
vector
context
aav
three
serotyp
five
test
show
transcytosi
abil
serotyp
celltyp
specif
serotyp
switch
achiev
transfect
plasmid
differ
capsid
backbon
therefor
valuabl
tool
transcytosi
aav
requir
coupl
ad
vector
adaptor
target
transferrinreceptor
pathway
enabl
transcytosi
albeit
low
effici
exploit
transcytosi
pathway
elucid
natur
transcytosi
pathway
virus
might
allow
ration
design
transcytos
vector
furthermor
gener
vector
mosaic
viral
attach
protein
two
genet
distinct
version
could
prove
valuabl
fig
one
attach
protein
could
carri
ligand
transcytosi
wherea
could
carri
ligand
transduct
target
cell
altern
transcytosi
ligand
could
place
onto
capsid
protein
exampl
pix
case
ad
transduct
ligand
viral
attach
protein
besid
improv
establish
vector
system
new
virus
also
develop
target
gene
therapi
one
promis
exampl
measl
viru
envelop
viru
recent
retarget
tumour
cell
exploit
oncolyt
potenti
contrast
retrovirus
attach
fusion
function
measl
viru
encod
separ
protein
easier
manipul
bind
specif
without
neg
impact
effici
cell
entri
sever
larg
polypeptid
ligand
display
surfac
measl
viru
extens
viral
attach
glycoprotein
case
liganddisplay
measl
virus
abl
enter
cell
effici
via
target
receptor
mutat
known
ablat
natur
measl
tropism
slam
signal
lymphocyt
activ
molecul
subsequ
incorpor
chimer
viral
attach
protein
therebi
gener
fulli
retarget
measl
virus
entir
new
receptor
specif
sever
fulli
retarget
measl
virus
shown
mediat
target
vivo
destruct
receptorposit
tumour
way
new
genetransf
vehicl
creat
combin
establish
target
principl
ablat
nativ
tropism
target
singlechain
antibodi
natur
abil
differ
vector
thu
continu
expand
gene
therapist
toolbox
concept
vector
target
describ
review
recogn
throughout
gene
therapi
field
regard
nonvir
vector
effici
gene
transfer
system
deliveri
low
unless
vector
administ
high
pressur
exampl
hydrodynam
deliveri
mice
select
transduc
liver
nonvir
vector
essenti
dnacontain
nanoparticl
retarget
incorpor
ligand
lipid
protein
shell
date
convinc
studi
demonstr
vivo
util
retarget
nonvir
vector
howev
effici
approach
viral
vector
target
principl
outlin
review
also
like
applic
nonvir
vector
